Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Ensysce Biosciences, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +3 vs. Q1 2026
- Shares held
- 904.7K
- +417.7K (+85.8%) vs. Q1 2026
- Total value
- $261.1K
- −$430 (−0.2%) vs. Q1 2026
- New holders
- 5
- 5 more added
- Sold out
- 2
- 1 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FNY Investment Advisers, LLC | 3,000 | $0 | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 1 | $0 | 0.00% | +1 | New |
| BlackRock, Inc. | 65 | $19 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 641 | $186 | 0.00% | +155+31.9% | Added |
| Barclays PLC | 1,440 | $418 | 0.00% | +1,440 | New |
| Tower Research Capital LLC (TRC) | 6,094 | $1.77K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 12,854 | $3.73K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 12,953 | $3.76K | 0.00% | +12,953 | New |
| Tru Independence Asset Management 2, LLC | 13,000 | $3.77K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 34,280 | $9.94K | 0.00% | +34,280 | New |
| HRT Financial LP | 54,429 | $15.0K | 0.00% | +54,429 | New |
| Geode Capital Management, LLC | 62,188 | $18.0K | 0.00% | −11,692−15.8% | Reduced |
| XTX Topco Ltd | 77,005 | $22.3K | 0.00% | +52,642+216.1% | Added |
| Citadel Advisors LLC | 86,193 | $25.0K | 0.00% | +28,830+50.3% | Added |
| Perceptive Advisors LLC | 86,666 | $25.1K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 95,391 | $28.0K | 0.00% | +82,078+616.5% | Added |
| Adage Capital Partners GP, L.L.C. | 149,711 | $43.4K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 208,833 | $60.6K | 0.00% | +195,263+1,438.9% | Added |
| Vanguard Fiduciary Trust Co | 0 | $0 | 0.00% | −23,854−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8,791−100.0% | Sold out |